Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc., commonly referred to as Intercept, is a leading biopharmaceutical company headquartered in the United States. Founded in 2002, the company has established itself in the liver disease sector, focusing on innovative therapies for chronic liver conditions. With a strong presence in North America and Europe, Intercept is dedicated to addressing unmet medical needs in hepatology. The company’s flagship product, Ocaliva (obeticholic acid), is a groundbreaking treatment for primary biliary cholangitis, setting a new standard in patient care. Intercept's commitment to research and development has positioned it as a key player in the industry, with a robust pipeline aimed at advancing liver disease treatment. Notable achievements include significant clinical trial successes and a growing reputation for excellence in the biopharmaceutical landscape.
DitchCarbon Score
How does Intercept Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Intercept Pharmaceuticals's score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Intercept Pharmaceuticals's reported carbon emissions
Intercept Pharmaceuticals, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The company is classified as a current subsidiary of Intercept Pharmaceuticals, Inc., and as such, it does not inherit emissions data from a parent organisation. While there are no specific emissions figures or climate commitments disclosed, the absence of data suggests that Intercept Pharmaceuticals may still be in the process of establishing its climate strategy. The company has not outlined any Science-Based Targets initiative (SBTi) commitments or other significant climate pledges, indicating a potential area for future development in sustainability practices. In the broader context of the pharmaceutical industry, companies are increasingly recognising the importance of addressing climate change and reducing carbon footprints. As Intercept Pharmaceuticals moves forward, it may consider aligning with industry standards and setting measurable targets to enhance its environmental performance.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Intercept Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
